Wasdell to build Irish packaging and testing site, secures EU base

By Flora Southey contact

- Last updated on GMT

GettyImages/bjeayes
GettyImages/bjeayes
Wasdell Group will invest €30m in a packaging, testing and distribution facility in Ireland, which it says could help UK and US customers serve European clients post-Brexit.

The 70,000 square-foot Dundalk facility – located between Dublin and Belfast – will offer qualified person (QP) release, analytical testing and distribution services.

The site will also provide primary and secondary pharmaceutical packaging services, including blister packing and container filling.

The UK-headquartered firm said the project is supported by IDA Ireland (previously the Industrial Development Authority), and would create more than 300 jobs over five years.

Ireland’s Minister for State for Employment and Small Business Pat Breen said the site’s location responds to a government push to disperse job allocation across the Green Isle.

“The government has been driving job creation in locations which are away from the bigger cities, and this new operation in Dundalk is a great vindication of that policy,” ​he said at the site announcement.

A European link

Wasdell’s managing director Martin Tedham said the new facility could help firms continue to serve European customers.

“We have always had a strong customer base in Ireland and we are certain that this trend will continue with the impending Brexit situation as companies typically from the UK and the USA look to securing a base to service their European markets,” ​he said in a statement.

The facility also represents an “example of the type of Brexit linked opportunity IDA Ireland is working hard to secure,” ​said the government agency’s CEO Martin Shanahan.

Wasdell will be looking to fill positions in management, QA/QC, laboratory, engineering and maintenance, production operatives, warehouse, finance and administration, health and safety, and human resources.

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers